FULC Fulcrum Therapeutics

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 10:30 a.m. ET/7:30 a.m. PT.

A live webcast of the presentation will be accessible or by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at . A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit and follow us on X (@FulcrumTx) and LinkedIn.

Contact:

Kevin Gardner

LifeSci Advisors, LLC



617-283-2856



EN
07/01/2026

Underlying

FULCFulcrum Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fulcrum Therapeutics

 PRESS RELEASE
Free
FULC Fulcrum Therape...

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Hea...

Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of the presentation will be accessible o...

January 7, 2026 1 EN
 PRESS RELEASE
Free
FULC Fulcrum Therape...

Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Publi...

Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the pricing of its previously announced underwritten public offering of 11,851,853 shares of its common stock at a public offering price of $13.50 per share, and, in lieu of common stock to certa...

December 10, 2025 1 EN
 PRESS RELEASE
Free
FULC Fulcrum Therape...

Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering...

Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock. Fulcrum also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its c...

December 8, 2025 1 EN
 PRESS RELEASE
Free
FULC Fulcrum Therape...

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg...

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting ― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at Week 6 (vs. 5.6% at Week 6 in the 12 mg cohort); 7 of 12 patients in the 20 mg cohort (58%) achieved absolute HbF levels ≥20% ― ― >3.75-fold mean induction of HbF at Week 12 in the 20 mg cohort...

December 6, 2025 1 EN
 PRESS RELEASE
Free
FULC Fulcrum Therape...

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Ru...

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as ...

December 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch